Proximagen, GlaxoSmithKline deal

Proximagen said in its 1H11 earnings that it acquired exclusive, worldwide rights to two positive allosteric modulators programs from GlaxoSmithKline. When Proximagen announced the deal last December it said the most advanced program, which was in preclinical development, targets the nicotinic acetylcholine receptor alpha-7 ( CHRNA7), while the second program targets the dopamine D1 receptor. Proximagen said the compounds have potential to treat CNS disorders, including cognition, neuropathic pain and Parkinson's disease (PD). Details were not disclosed. ...